Satyavrat Shukla

2021

In 2021, Satyavrat Shukla earned a total compensation of $2.2M as Chief Financial Officer at Spero Therapeutics.

Compensation breakdown

Bonus$164,000
Non-Equity Incentive Plan$175,660
Option Awards$1,039,433
Salary$440,889
Stock Awards$399,994
Other$8,295
Total$2,228,271

Shukla received $1M in option awards, accounting for 47% of the total pay in 2021.

Shukla also received $164K in bonus, $175.7K in non-equity incentive plan, $440.9K in salary, $400K in stock awards and $8.3K in other compensation.

Rankings

In 2021, Satyavrat Shukla's compensation ranked 5,616th out of 12,415 executives tracked by ExecPay. In other words, Shukla earned more than 54.8% of executives.

ClassificationRankingPercentile
All
5,616
out of 12,415
55th
Division
Manufacturing
2,378
out of 5,501
57th
Major group
Chemicals And Allied Products
1,032
out of 2,371
57th
Industry group
Drugs
921
out of 2,092
56th
Industry
Pharmaceutical Preparations
663
out of 1,542
57th
Source: SEC filing on August 5, 2022.

Shukla's colleagues

We found three more compensation records of executives who worked with Satyavrat Shukla at Spero Therapeutics in 2021.

2021

Ankit Mahadevia

Spero Therapeutics

Chief Executive Officer

2021

Cristina Larkin

Spero Therapeutics

Chief Operating Officer

2021

Tamara Joseph

Spero Therapeutics

Chief Legal Officer

News

You may also like